Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.39 |
| ▸ | CTSK | P43235 | 6/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.34 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30090985 | 0.94 | CTSS (0.40) | CTSSCTSKPSMB5TMPRSS2SCN9A | |
| SCHEMBL30091067 | 0.94 | CTSS (0.40) | CTSSCTSKPSMB5TMPRSS2SCN9A | |
| SCHEMBL25909906 | 0.93 | CTSS (0.41) | CTSSCTSKPSMB5TMPRSS2SCN9A | |
| SCHEMBL25909468 | 0.92 | CTSS (0.40) | CTSSCTSKPSMB5TMPRSS2SCN9A | |
| SCHEMBL30090949 | 0.92 | CTSS (0.39) | CTSSCTSKPSMB5TMPRSS2SCN9A | |
| SCHEMBL30090961 | 0.91 | CTSS (0.37) | CTSSCTSKPSMB5TMPRSS2SCN9A | |
| SCHEMBL25909472 | 0.91 | CTSS (0.42) | CTSSCTSKPSMB5TMPRSS2SCN9A | |
| SCHEMBL25909446 | 0.91 | CTSS (0.42) | CTSSCTSKPSMB5TMPRSS2SCN9A | |
| SCHEMBL30090953 | 0.90 | CTSS (0.40) | CTSSCTSKPSMB5TMPRSS2SCN9A | |
| SCHEMBL24917073 | 0.90 | CTSS (0.36) | CTSSCTSKPSMB5TMPRSS2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355755-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | CTSS 1351/4885CTSK 1444/4885PSMB5 4748/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | CTSS 1351/4885CTSK 1444/4885PSMB5 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.